Topical Application of the Anti-Microbial Chemical Triclosan Induces Immunomodulatory Responses Through the S100A8/A9-TLR4 Pathway
Public Domain
-
2017/01/01
-
Details
-
Personal Author:
-
Description:The anti-microbial compound triclosan is incorporated into numerous consumer products and is detectable in the urine of 75% of the general United States population. Recent epidemiological studies report positive associations with urinary triclosan levels and allergic disease. Although not sensitizing, earlier studies previously found that repeated topical application of triclosan augments the allergic response to ovalbumin (OVA) though a thymic stromal lymphopoietin (TSLP) pathway in mice. In the present study, early immunological effects following triclosan exposure were further evaluated following topical application in a murine model. These investigations revealed abundant expression of S100A8/A9, which reportedly acts as an endogenous ligand for Toll-like Receptor 4 (TLR4), in skin tissues and in infiltrating leukocytes during topical application of 0.75-3.0% triclosan. Expression of Tlr4 along with Tlr1, Tlr2 and Tlr6 increased in skin tissues over time with triclosan exposure; high levels of TLR4 were expressed on skin-infiltrating leukocytes. In vivo antibody blockade of the TLR4/MD-2 receptor complex impaired local inflammatory responses after four days, as evidenced by decreased Il6, Tnfa, S100a8, S100a9, Tlr1, Tlr2, Tlr4 and Tlr6 expression in the skin and decreased lymph node cellularity and production of IL-4 and IL-13 by lymph node T-cells. After nine days of triclosan exposure with TLR4/MD-2 blockade, impaired T-helper cell type 2 (TH2) cytokine responses were sustained, but other early effects on skin and lymph node cellularity were lost; this suggested alternative ligands/receptors compensated for the loss of TLR4 signaling. Taken together, these data suggest the S100A8/A9-TLR4 pathway plays an early role in augmenting immunomodulatory responses with triclosan exposure and support a role for the innate immune system in chemical adjuvancy. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:1547-691X
-
Document Type:
-
Genre:
-
Place as Subject:
-
CIO:
-
Division:
-
Topic:
-
Location:
-
Pages in Document:50-59
-
Volume:14
-
Issue:1
-
NIOSHTIC Number:nn:20050203
-
Citation:J Immunotoxicol 2017 Jan; 14(1):50-59
-
Contact Point Address:Stacey E. Anderson, Allergy and Clinical Immunology Branch, CDC-NIOSH, 1095 Willowdale Road, m/s 4020, Morgantown, WV 26505, USA
-
Email:sanderson4@cdc.gov
-
CAS Registry Number:
-
Federal Fiscal Year:2017
-
NORA Priority Area:
-
Peer Reviewed:True
-
Source Full Name:Journal of Immunotoxicology
-
Collection(s):
-
Main Document Checksum:urn:sha-512:fa6d9e0b2d2ad4c317b083a6c9098cd409218e70120f927bc90fe958d834851451d5e9898018907258ab0bdba577e03394c04832448724ff447f41ea77c57c7f
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like